Varseta-M turns the pivotal corner: CytomX's EpCAM ADC owns the 2H catalyst
Dose-optimization enrollment complete — 113-patient Phase I, $346.7M cash, and an 80% revenue drop that is actually a deliberate reset.
CTMX · Earnings Call · 2026-05-07
The clinical fulcrum is Varseta-M
When CytomX's chairman and CEO opened the first-quarter call talking about a "transformational year," the foundation was exactly one molecule: Varseta-M, the first-in-class EpCAM-directed antibody-drug conjugate (ADC) built on the company's PROBODY masking platform. Management's confidence rests on a stark biological claim —The platform's payoff is now measurable in the clinic. CytomX completed enrollment in the dose optimization cohorts — 40 patients across the 8.6 and 10 mg/kg doses, both evaluated on an adjusted ideal body weight basis — pulling total Phase I enrollment to 113 patients. That data set, read out by the end of this year, is the critical catalyst: it feeds dose selection under Project Optimus, the patient-population definition, and the comparator arm for the first registrational study targeted in 1H 2027. Management was explicit about scope and timing: “we are expecting that the update in the second half will be fairly substantial... we've now enrolled 113 patients across the dose escalation, expansion and now optimization phases of the study.” — Sean McCarthy, Chairman and Chief Executive Officer · 2026-05-07 FDA interactions are set to run through 2026, with the optimization data central to those dose-selection conversations. The efficacy bar is already high: the March 2026 data disclosed a confirmed overall response rate between 20% and 32% and roughly seven months of median progression-free survival in heavily-pretreated metastatic CRC — versus single-digit ORRs and a few months of PFS for current late-line options. The unheralded piece is the safety book that makes the efficacy translatable. The principal adverse event, high-grade diarrhea, has been managed with a dual prophylaxis regimen (loperamide plus budesonide) layered on adjusted ideal body weight dosing, which compresses the pharmacokinetic outliers. The early read from the first 20 optimization patients showed Grade 3 diarrhea at roughly 10% versus a historical 25–30%, with management's stated goal to hold it in the 10–20% band. As McCarthy summed it for analysts: “our objective is, of course, to manage the rate of Grade 3 to the best of our ability with this updated AE management strategy that includes upfront use of loperamide and budesonide.” — Sean McCarthy, Chairman and Chief Executive Officer · 2026-05-07 This is a story that has been building deliberately across quarters. In March management flagged the increasingly third-line-oriented pivotal posture: “We, of course, need to learn about OS and we'll be sharing OS data as the program matures. That will be a key determiner of our decision-making on the pivotal design.” — Sean McCarthy, Chief Executive Officer · 2026-03-16 The November 2025 call was equally pointed on the underlying activity: “we saw an integrated confirmed response rate of 28%, which very substantially beats the current standard of care in the late-line setting, where, as you know, response rates are in the single digits.” — Sean McCarthy, Chairman and Chief Executive Officer · 2025-11-07 The second-half 2026 update is now expected to add initial OS data from the earlier escalation/expansion cohorts — effectively the final go/no-go before the pivotal begins.In our view and based on our preclinical data and efforts of others over many years, we believe we can say with confidence that a conventional unmasked ADC targeting EpCAM would have no chance of achieving dose levels that deliver meaningful anticancer activity due to severe on-target toxicities.